A new weight-loss medication called Wegovy, which comes as an easy-to-take pill instead of an injection, has been prescribed over 2 million times since it became available in January. This success comes despite tough competition from other weight-loss drugs, and it’s helping the company Novo Nordisk bounce back financially. In the first three months of 2026, Wegovy brought in about $360 million in sales, with over 1.3 million prescriptions filled just in that period. Since its launch, more than 2 million prescriptions have been written. During one week in April, doctors wrote over 200,000 prescriptions for Wegovy alone. In a recent earnings call, Novo Nordisk’s CEO, Mike Doustdar, called Wegovy’s start in the U.S. ‘record-breaking.’ He also said the company has found the ‘sweet spot’ with its pricing, which seems to be working well. For people paying out of pocket, the lowest dose costs $149 per month, the middle dose is $199 per month, and the highest dose is $299 per month. Eli Lilly, another company making weight-loss medications, launched a competing pill called Foundayo in April 2026. However, in its first three weeks, Foundayo was prescribed about 5,600 times—far fewer than Wegovy. Novo Nordisk plans to expand the availability of Wegovy to other countries later this year, which could help more people access the medication. Thanks to Wegovy’s strong start, Novo Nordisk has raised its sales forecast for 2026, predicting a smaller drop in growth than previously expected. In the first quarter of 2026, Novo Nordisk’s total sales grew by 32%, and its profits increased by 65%. Doustdar said the company is pleased with the progress but knows it has more work to do to keep expanding access to the medication for patients worldwide. Meanwhile, Eli Lilly also reported strong sales in the first quarter of 2026, with revenue growing by 56% compared to last year, further solidifying its position in the market for medications that treat conditions like diabetes and heart disease.